Hypoactive sexual desire disorder, or HSDD, is a persistent lack of interest in sexual activity that causes significant personal distress. It affects roughly 10% of women and 8% of men. The key distinction between HSDD and simply having a lower sex drive is that distress component: if you’re content with your level of desire, it’s not HSDD, regardless of how often you want sex.
How HSDD Is Defined
The formal diagnostic criterion is straightforward: a persistent or recurring absence of sexual fantasies and desire for sexual activity that causes marked distress or interpersonal difficulty. Both parts matter. A person with naturally low desire who feels fine about it doesn’t meet the criteria. Someone whose desire dropped sharply after a medication change and who feels frustrated, disconnected, or upset about it might.
HSDD can be lifelong (present since sexual maturity) or acquired (developing after a period of normal desire). It can also be generalized, meaning it applies in all situations, or situational, meaning desire is absent only with certain partners or in certain contexts. These distinctions help pinpoint what’s driving the problem.
It’s worth noting that the diagnostic landscape has shifted. The most recent edition of the DSM, used by mental health professionals, merged HSDD and a related arousal condition into a broader diagnosis called female sexual interest/arousal disorder (FSIAD) for women. That diagnosis requires at least three of six specific symptoms lasting six months or more. Despite this reclassification, “HSDD” remains the term most clinicians and researchers use in practice, and it’s still the diagnosis referenced by the FDA for approved treatments.
What Happens in the Brain
Sexual desire works on a balance system in the brain, sometimes called the dual-control model. One set of signals pushes desire up (excitation), and another set pushes it down (inhibition). Desire happens when the excitatory signals outweigh the inhibitory ones. HSDD can develop when that balance tips in either direction: too little excitation, too much inhibition, or both.
On the excitation side, dopamine is the main player. It drives motivation and the pursuit of reward, including sexual activity. Norepinephrine supports that by promoting general arousal and focused engagement. On the inhibition side, serotonin acts as a brake. It promotes feelings of satiety and dampens reward-seeking behavior, which is why antidepressants that boost serotonin (SSRIs) so commonly reduce sexual desire as a side effect.
Brain imaging studies in women with HSDD show reduced activity in regions tied to sexual desire and increased activity in areas associated with self-monitoring and moral judgment. In other words, the brain’s “go” signals are quieter while the “stop and evaluate” signals are louder. There’s no single broken pathway, though. Many different combinations of neurochemical shifts can produce the same outcome.
Common Causes and Contributors
HSDD rarely traces back to one neat cause. It typically involves a mix of biological, psychological, and relational factors layered on top of each other.
On the biological side, hormonal changes are a frequent trigger, particularly drops in testosterone and estrogen during menopause or after surgical removal of the ovaries. Chronic conditions like diabetes, thyroid disorders, and cardiovascular disease can also dampen desire. Medications are another major contributor. SSRIs are the most well-known culprits, but hormonal contraceptives, blood pressure medications, and opioid pain relievers can all interfere with the neurochemistry of desire.
Psychological factors carry just as much weight. Depression and anxiety create a mental burden that pulls focus away from sexual experiences. Negative body image and low self-esteem can undermine feelings of desirability. Stress, whether from work, caregiving, or financial pressure, competes directly with the mental space that sexual interest requires.
Relationship dynamics matter too. Emotional distance, unresolved conflict, poor communication, and lack of trust can all erode desire over time. Conversely, people in supportive, emotionally connected relationships tend to report higher levels of sexual interest. This is why clinicians typically look at the full picture, not just hormones or brain chemistry, before recommending treatment.
How It’s Identified
There’s no blood test for HSDD. Diagnosis relies on a clinical conversation and, often, validated screening questionnaires. One widely used tool, the Sexual Interest and Desire Inventory, flags the likely presence of HSDD when scores fall at or below 33. The Decreased Sexual Desire Screener is a shorter option designed for quick use in a primary care setting.
A thorough evaluation also involves ruling out other explanations. Your provider will typically ask about medications, mental health history, relationship satisfaction, life stressors, and any medical conditions that could be suppressing desire. If an SSRI is the obvious trigger, for example, the first step might be adjusting that medication rather than adding a new one.
Treatment Options for Women
Two prescription medications are currently approved in the United States specifically for HSDD in premenopausal women. The first, flibanserin (sold as Addyi), is a daily pill taken at bedtime. It works by adjusting the balance between serotonin, dopamine, and norepinephrine in the brain, essentially dialing down the inhibitory brake while boosting excitatory signals. It takes up to eight weeks to know if it’s working, and if there’s no improvement by then, it should be stopped. The most common side effects are dizziness, sleepiness, nausea, and fatigue, which is why bedtime dosing is required.
The second option, bremelanotide (Vyleesi), takes a different approach. It’s a self-administered injection given at least 45 minutes before anticipated sexual activity, rather than taken daily. It activates a receptor in the brain involved in regulating sexual desire and appetite. In clinical trials, it improved desire scores and reduced sexual distress in a meaningful portion of participants. Nausea is the most notable side effect.
For postmenopausal women, low-dose testosterone delivered through the skin (as a patch or gel) is the most evidence-supported option. International clinical guidelines identify it as the sole evidence-based hormonal therapy for HSDD in this population. Because no testosterone product is specifically approved for women, it’s prescribed off-label, typically at about one-tenth of the male dose. At these physiologic levels, clinical trials lasting 24 weeks found increases in acne and mild hair growth but no serious adverse effects. Oral testosterone is not recommended due to potential negative effects on cholesterol.
The Role of Therapy
Psychological treatment, particularly cognitive behavioral therapy (CBT), has strong evidence behind it. A systematic review found that CBT produced a large positive effect on sexual desire scores compared to no treatment. The approach works by helping people identify and challenge the thought patterns that suppress desire: beliefs about sex being shameful, assumptions about what a partner thinks, or automatic negative self-talk about one’s body.
Mindfulness-based techniques are often combined with CBT. These help people disengage from the self-critical or anxious thoughts that intrude during sexual experiences. In one study, 86% of women with low desire found that cognitive restructuring techniques helped them move past maladaptive thinking patterns. Sex therapy, which directly addresses communication, expectations, and physical intimacy practices within a relationship, is another common approach, sometimes used alongside medication.
For many people, the most effective path combines more than one treatment. Addressing a medication side effect, working through relationship tension in therapy, and using a pharmacological option can all reinforce each other. The goal isn’t to hit some arbitrary frequency of sexual activity. It’s to reduce the gap between the desire you want to feel and what you’re actually experiencing, and to relieve the distress that gap creates.